Table 1. Open in new tab Characteristics...

Characteristics	Patients receiving TCZ (N = 839)
Total PY	718.4
Female, n (%)	646 (77.0)
Age, years, mean (SD)	59.6 (13.5)
Median, range	62 (15–90)
≥ 65, n (%)	335 (39.9)
Body weight, kg, mean (SD)	54.4 (10.7)
Body weight <40 kg, n (%)	35 (4.2)
Disease duration, years, mean (SD)	7.5 (8.9)
Median, range	3.5 (0.0–54.4)
History of comorbidities, n (%)	319 (38.0)
Appendicitis	23 (2.7)
Uterine leiomyoma	18 (2.1)
Interstitial lung disease	18 (2.1)
Tuberculosis	16 (1.9)
Pneumonia	13 (1.5)
Gastric ulcer	13 (1.5)
Breast cancer	12 (1.4)
Comorbidities, n (%)	483 (57.6)
Hypertension	154 (18.4)
Osteoporosis	153 (18.2)
Hyperlipidemia	91 (10.8)
Diabetes mellitus	70 (8.3)
Interstitial lung disease	52 (6.2)
Gastritis	48 (5.7)
Gastroesophageal reflux disease	34 (4.1)
Anemia	27 (3.2)
Clinical characteristics
Steinbrocker radiographic stage, n (%)
I	216 (25.7)
II	290 (34.6)
III	184 (21.9)
IV	149 (17.8)
Steinbrocker functional class, n (%)
1	156 (18.6)
2	524 (62.5)
3	145 (17.3)
4	14 (1.7)
RF +, (%)	64.5
Baseline DAS28-ESR, mean (SD)	5.2 (1.2)
Baseline CDAI, mean (SD)	23.3 (11.8)
Baseline HAQ-DI, mean (SD)	1.0 (0.8)
Baseline CRP, mg/dl, mean (SD)	2.4 (2.8)
Baseline ESR, mm/h, mean (SD)	46.2 (30.1)
Concomitant csDMARD use, n (%)^a	681 (81.2)
Concomitant MTX, n (%)^a	526 (62.7)
MTX dose, mg/week, mean (SD)	9.1 (3.9)
MTX dose, mg/week, min–max	2.0–64.0^b
Concomitant oral corticosteroid use, n (%)^a	440 (52.4)
Corticosteroid dose, mg/d, mean (SD)	5.4 (3.2)
Corticosteroid dose, mg/d, min–max	0.5–25.0

Characteristics

Patients receiving TCZ (N = 839)

Total PY

718.4

Female, n (%)

646 (77.0)

Age, years, mean (SD)

59.6 (13.5)

Median, range

62 (15–90)

≥ 65, n (%)

335 (39.9)

Body weight, kg, mean (SD)

54.4 (10.7)

Body weight <40 kg, n (%)

35 (4.2)

Disease duration, years, mean (SD)

7.5 (8.9)

Median, range

3.5 (0.0–54.4)

History of comorbidities, n (%)

319 (38.0)

Appendicitis

23 (2.7)

Uterine leiomyoma

18 (2.1)

Interstitial lung disease

18 (2.1)

Tuberculosis

16 (1.9)

Pneumonia

13 (1.5)

Gastric ulcer

13 (1.5)

Breast cancer

12 (1.4)

Comorbidities, n (%)

483 (57.6)

Hypertension

154 (18.4)

Osteoporosis

153 (18.2)

Hyperlipidemia

91 (10.8)

Diabetes mellitus

70 (8.3)

Interstitial lung disease

52 (6.2)

Gastritis

48 (5.7)

Gastroesophageal reflux disease

34 (4.1)

Anemia

27 (3.2)

Clinical characteristics

Steinbrocker radiographic stage, n (%)

216 (25.7)

290 (34.6)

III

184 (21.9)

149 (17.8)

Steinbrocker functional class, n (%)

156 (18.6)

524 (62.5)

145 (17.3)

14 (1.7)

RF +, (%)

64.5

Baseline DAS28-ESR, mean (SD)

5.2 (1.2)

Baseline CDAI, mean (SD)

23.3 (11.8)

Baseline HAQ-DI, mean (SD)

1.0 (0.8)

Baseline CRP, mg/dl, mean (SD)

2.4 (2.8)

Baseline ESR, mm/h, mean (SD)

46.2 (30.1)

Concomitant csDMARD use, n (%)^a

681 (81.2)

Concomitant MTX, n (%)^a

526 (62.7)

MTX dose, mg/week, mean (SD)

9.1 (3.9)

MTX dose, mg/week, min–max

2.0–64.0^b

Concomitant oral corticosteroid use, n (%)^a

440 (52.4)

Corticosteroid dose, mg/d, mean (SD)

5.4 (3.2)

Corticosteroid dose, mg/d, min–max

0.5–25.0

Characteristics	Patients receiving TCZ (N = 839)
Total PY	718.4
Female, n (%)	646 (77.0)
Age, years, mean (SD)	59.6 (13.5)
Median, range	62 (15–90)
≥ 65, n (%)	335 (39.9)
Body weight, kg, mean (SD)	54.4 (10.7)
Body weight <40 kg, n (%)	35 (4.2)
Disease duration, years, mean (SD)	7.5 (8.9)
Median, range	3.5 (0.0–54.4)
History of comorbidities, n (%)	319 (38.0)
Appendicitis	23 (2.7)
Uterine leiomyoma	18 (2.1)
Interstitial lung disease	18 (2.1)
Tuberculosis	16 (1.9)
Pneumonia	13 (1.5)
Gastric ulcer	13 (1.5)
Breast cancer	12 (1.4)
Comorbidities, n (%)	483 (57.6)
Hypertension	154 (18.4)
Osteoporosis	153 (18.2)
Hyperlipidemia	91 (10.8)
Diabetes mellitus	70 (8.3)
Interstitial lung disease	52 (6.2)
Gastritis	48 (5.7)
Gastroesophageal reflux disease	34 (4.1)
Anemia	27 (3.2)
Clinical characteristics
Steinbrocker radiographic stage, n (%)
I	216 (25.7)
II	290 (34.6)
III	184 (21.9)
IV	149 (17.8)
Steinbrocker functional class, n (%)
1	156 (18.6)
2	524 (62.5)
3	145 (17.3)
4	14 (1.7)
RF +, (%)	64.5
Baseline DAS28-ESR, mean (SD)	5.2 (1.2)
Baseline CDAI, mean (SD)	23.3 (11.8)
Baseline HAQ-DI, mean (SD)	1.0 (0.8)
Baseline CRP, mg/dl, mean (SD)	2.4 (2.8)
Baseline ESR, mm/h, mean (SD)	46.2 (30.1)
Concomitant csDMARD use, n (%)^a	681 (81.2)
Concomitant MTX, n (%)^a	526 (62.7)
MTX dose, mg/week, mean (SD)	9.1 (3.9)
MTX dose, mg/week, min–max	2.0–64.0^b
Concomitant oral corticosteroid use, n (%)^a	440 (52.4)
Corticosteroid dose, mg/d, mean (SD)	5.4 (3.2)
Corticosteroid dose, mg/d, min–max	0.5–25.0

Table 1.

Open in new tab

Characteristics of patients with RA participating in the FIRST Bio study.

Characteristics	Patients receiving TCZ (N = 839)
Total PY	718.4
Female, n (%)	646 (77.0)
Age, years, mean (SD)	59.6 (13.5)
Median, range	62 (15–90)
≥ 65, n (%)	335 (39.9)
Body weight, kg, mean (SD)	54.4 (10.7)
Body weight <40 kg, n (%)	35 (4.2)
Disease duration, years, mean (SD)	7.5 (8.9)
Median, range	3.5 (0.0–54.4)
History of comorbidities, n (%)	319 (38.0)
Appendicitis	23 (2.7)
Uterine leiomyoma	18 (2.1)
Interstitial lung disease	18 (2.1)
Tuberculosis	16 (1.9)
Pneumonia	13 (1.5)
Gastric ulcer	13 (1.5)
Breast cancer	12 (1.4)
Comorbidities, n (%)	483 (57.6)
Hypertension	154 (18.4)
Osteoporosis	153 (18.2)
Hyperlipidemia	91 (10.8)
Diabetes mellitus	70 (8.3)
Interstitial lung disease	52 (6.2)
Gastritis	48 (5.7)
Gastroesophageal reflux disease	34 (4.1)
Anemia	27 (3.2)
Clinical characteristics
Steinbrocker radiographic stage, n (%)
I	216 (25.7)
II	290 (34.6)
III	184 (21.9)
IV	149 (17.8)
Steinbrocker functional class, n (%)
1	156 (18.6)
2	524 (62.5)
3	145 (17.3)
4	14 (1.7)
RF +, (%)	64.5
Baseline DAS28-ESR, mean (SD)	5.2 (1.2)
Baseline CDAI, mean (SD)	23.3 (11.8)
Baseline HAQ-DI, mean (SD)	1.0 (0.8)
Baseline CRP, mg/dl, mean (SD)	2.4 (2.8)
Baseline ESR, mm/h, mean (SD)	46.2 (30.1)
Concomitant csDMARD use, n (%)^a	681 (81.2)
Concomitant MTX, n (%)^a	526 (62.7)
MTX dose, mg/week, mean (SD)	9.1 (3.9)
MTX dose, mg/week, min–max	2.0–64.0^b
Concomitant oral corticosteroid use, n (%)^a	440 (52.4)
Corticosteroid dose, mg/d, mean (SD)	5.4 (3.2)
Corticosteroid dose, mg/d, min–max	0.5–25.0

Characteristics	Patients receiving TCZ (N = 839)
Total PY	718.4
Female, n (%)	646 (77.0)
Age, years, mean (SD)	59.6 (13.5)
Median, range	62 (15–90)
≥ 65, n (%)	335 (39.9)
Body weight, kg, mean (SD)	54.4 (10.7)
Body weight <40 kg, n (%)	35 (4.2)
Disease duration, years, mean (SD)	7.5 (8.9)
Median, range	3.5 (0.0–54.4)
History of comorbidities, n (%)	319 (38.0)
Appendicitis	23 (2.7)
Uterine leiomyoma	18 (2.1)
Interstitial lung disease	18 (2.1)
Tuberculosis	16 (1.9)
Pneumonia	13 (1.5)
Gastric ulcer	13 (1.5)
Breast cancer	12 (1.4)
Comorbidities, n (%)	483 (57.6)
Hypertension	154 (18.4)
Osteoporosis	153 (18.2)
Hyperlipidemia	91 (10.8)
Diabetes mellitus	70 (8.3)
Interstitial lung disease	52 (6.2)
Gastritis	48 (5.7)
Gastroesophageal reflux disease	34 (4.1)
Anemia	27 (3.2)
Clinical characteristics
Steinbrocker radiographic stage, n (%)
I	216 (25.7)
II	290 (34.6)
III	184 (21.9)
IV	149 (17.8)
Steinbrocker functional class, n (%)
1	156 (18.6)
2	524 (62.5)
3	145 (17.3)
4	14 (1.7)
RF +, (%)	64.5
Baseline DAS28-ESR, mean (SD)	5.2 (1.2)
Baseline CDAI, mean (SD)	23.3 (11.8)
Baseline HAQ-DI, mean (SD)	1.0 (0.8)
Baseline CRP, mg/dl, mean (SD)	2.4 (2.8)
Baseline ESR, mm/h, mean (SD)	46.2 (30.1)
Concomitant csDMARD use, n (%)^a	681 (81.2)
Concomitant MTX, n (%)^a	526 (62.7)
MTX dose, mg/week, mean (SD)	9.1 (3.9)
MTX dose, mg/week, min–max	2.0–64.0^b
Concomitant oral corticosteroid use, n (%)^a	440 (52.4)
Corticosteroid dose, mg/d, mean (SD)	5.4 (3.2)
Corticosteroid dose, mg/d, min–max	0.5–25.0

^aConcomitant use at baseline.

^bOne patient received 64.0 mg/week of MTX for 1 week due to incorrect administration before starting TCZ treatment. After that, the patient received 4 mg/week of MTX.

CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28-ESR, Disease Activity Score based on 28-joint-erythrocyte sedimentation rate; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; PY, patient-years; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; TCZ, tocilizumab.

This Feature Is Available To Subscribers Only